Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis
- PMID: 17014016
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis
Abstract
Objective: T cell activation plays a pivotal role in the immunopathogenesis of systemic sclerosis (SSc). Lymphocyte processes are tightly controlled by molecules activating either proliferation or programmed cell death (apoptosis). We investigated whether an imbalance in apoptotic function, increasing the survival rate of autoreactive cells, may lead to persistent autoreactive phenomena.
Methods: We studied peripheral a/b and g/d T lymphocytes of 22 patients with SSc and 22 healthy controls for their spontaneous and stimulated (phytohemagglutinin, dexamethasone) apoptotic rate and surface phenotype including expression of Fas (CD95) and Bcl-2, determined by flow cytometry. sFas and sFas ligand in sera and supernatants were measured by ELISA. Caspase-3 activation in response to agonistic anti-Fas Mab treatment was assessed.
Results: Lymphocytes of SSc patients showed a significant decrease in the percentage of apoptotic cells over time, in both unstimulated and stimulated cultures, compared to controls. We observed no difference between patients and controls, in stimulated or unstimulated cells, in the phenotypic expression of apoptotic cells, including surface Fas. SSc T cells were less susceptible to undergoing apoptosis after anti-Fas stimulation. We observed a significant decrease of apoptotic cells from stimulated culture of isolated SSc g/d T cells. Serum levels of sFas in SSc patients were significantly higher compared to controls. Similar data were obtained in the supernatants of stimulated and unstimulated cultures. By contrast, sFas ligand was always reduced. Bcl-2 expression in SSc was significantly elevated. A significant decrease in caspase-3 activity was detected in SSc patients after treatment by agonistic anti-Fas antibody.
Conclusion: Resistance to apoptosis is present in a/b and g/d T cell lymphocyte subsets of patients with SSc, and several pathways seem to be connected in this setting.
Similar articles
-
Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.Cell Immunol. 2006 Feb;239(2):121-8. doi: 10.1016/j.cellimm.2006.05.003. Epub 2006 Jun 30. Cell Immunol. 2006. PMID: 16808908
-
Involvement of the Fas/Fas ligand pathway in activation-induced cell death of mycobacteria-reactive human gamma delta T cells: a mechanism for the loss of gamma delta T cells in patients with pulmonary tuberculosis.J Immunol. 1998 Aug 1;161(3):1558-67. J Immunol. 1998. PMID: 9686624
-
The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus.Cell Immunol. 2005 Jun;235(2):117-21. doi: 10.1016/j.cellimm.2005.08.031. Epub 2005 Oct 13. Cell Immunol. 2005. PMID: 16226734
-
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients.Arthritis Rheum. 1998 Feb;41(2):327-34. doi: 10.1002/1529-0131(199802)41:2<327::AID-ART17>3.0.CO;2-S. Arthritis Rheum. 1998. PMID: 9485091 Review.
-
Immunologic aspects of scleroderma.Curr Opin Rheumatol. 1992 Dec;4(6):862-8. Curr Opin Rheumatol. 1992. PMID: 1457282 Review.
Cited by
-
Apoptosis modulation as a promising target for treatment of systemic sclerosis.Int J Rheumatol. 2011;2011:495792. doi: 10.1155/2011/495792. Epub 2011 Sep 6. Int J Rheumatol. 2011. PMID: 21912551 Free PMC article.
-
Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis.Rheumatol Int. 2010 May;30(7):871-8. doi: 10.1007/s00296-009-1068-3. Epub 2009 Jul 29. Rheumatol Int. 2010. PMID: 19639321
-
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.Rheumatology (Oxford). 2022 Oct 6;61(10):4155-4162. doi: 10.1093/rheumatology/keac015. Rheumatology (Oxford). 2022. PMID: 35108379 Free PMC article.
-
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.Clin Exp Immunol. 2013 Aug;173(2):195-206. doi: 10.1111/cei.12111. Clin Exp Immunol. 2013. PMID: 23607751 Free PMC article.
-
Proteasome inhibition prevents development of experimental dermal fibrosis.Inflammation. 2012 Jun;35(3):810-7. doi: 10.1007/s10753-011-9380-y. Inflammation. 2012. PMID: 21882074
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous